Amy E DeZern

14PUBLICATIONS
102CO-AUTHORS
Regenerative medicine (incl. stem cells)Gene and molecular therapyHaematological tumoursPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Feb 16, 2026
Modeling the evolutionary dynamics of clonal hematopoiesis.

Sadegh Marzban, Thomas Stiehl, Zhuoer Xie

|Feb 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur

|Dec 03, 2025
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.

Carmelo Gurnari, Hideki Makishima, Arda Durmaz

|Nov 24, 2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Theodoros Karantanos, Nour Naji, Taha Ahmedna

Pageof 3

Frequent Collaborators

3 joint publications

Alexander J Ambinder

3 joint publications

Zhuoer Xie

3 joint publications

Rami S Komrokji

3 joint publications

Yasmin Abaza